Jeffrey B. Mirviss - Aug 28, 2023 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: EVP&Pres, Periph Intervent
Signature: /s/ Susan Thompson, Attorney-in-Fact
Stock symbol: BSX
Transactions as of: Aug 28, 2023
Transactions value $: -$996,230
Form type: 4
Date filed: 8/30/2023, 04:10 PM
Previous filing: Apr 6, 2023
Next filing: Nov 9, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BSX	Common Stock	Sale	-$742K	-14K	-17.64%	$53.14	65.2K	Aug 28, 2023	Direct	F1, F2
transaction	BSX	Common Stock	Sale	-$254K	-4.66K	-7.14%	$54.50	60.6K	Aug 29, 2023	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 25, 2023.
F2	Includes shares acquired on June 30, 2023 under the Boston Scientific Employee Stock Purchase Plan based upon the most current data available.
F3	Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $54.50 to $54.51, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.